Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of ant...
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
About this item
Full title
Author / Creator
Lamanna, Nicole , Tam, Constantine S. , Woyach, Jennifer A. , Alencar, Alvaro J. , Palomba, M. Lia , Zinzani, Pier Luigi , Flinn, Ian W. , Fakhri, Bita , Cohen, Jonathon B. , Kontos, Arrin , Konig, Heiko , Ruppert, Amy S. , Chatterjee, Anindya , Sizelove, Richard , Compte, Livia , Tsai, Donald E. and Jurczak, Wojciech
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Clinical bleeding events are reported here from 773 patients with B‐cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of antithrombotic therapy (antithrombotic exposed [AT‐E], n = 216; antithrombotic nonexposed [AT‐NE], n = 557). Among...
Alternative Titles
Full title
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_82cd9c8755ab4351873ea8a263b45176
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_82cd9c8755ab4351873ea8a263b45176
Other Identifiers
ISSN
2688-6146
E-ISSN
2688-6146
DOI
10.1002/jha2.1013
